| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Feb 22, 2017 | IRWD Ironwood Pharmaceuticals Inc | McCourt Thomas A66 | Chief Commercial Officer | Sell | 1,520 | $16.94 | $25,748.80 | -5.1% | |
| Feb 22, 2017 | ANIK Anika Therapeutics, Inc. | Land Raymond J | Director | Sell | 2,635 | $49.08 | $129,325.80 | -16.3% | |
| Feb 22, 2017 | IRWD Ironwood Pharmaceuticals Inc | Consylman Gina | Chief Accounting Officer | Sell | 1,839 | $16.94 | $31,152.66 | -2.9% | |
| Feb 22, 2017 | IRWD Ironwood Pharmaceuticals Inc | Gilbert Halley E | Chief Legal Officer | Sell | 5,039 | $16.94 | $85,360.66 | -3.9% | |
| Feb 22, 2017 | IRWD Ironwood Pharmaceuticals Inc | Graney Thomas | Chief Financial Officer | Sell | 1,874 | $16.94 | $31,745.56 | -4.2% | |
| Feb 21, 2017 | PAHC Phibro Animal Health Corp | Carlson Gerald K | Director | Sell | 12,000 | $29.08 | $348,960.00 | -100% | |
| Feb 17, 2017 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 230,000 | $80.27 | $18,462,790.00 | -0.2% | |
| Feb 16, 2017 | PAHC Phibro Animal Health Corp | Welch Daniel A | Sr VP, Human Resources | Sell | 5,000 | $29.55 | $147,750.00 | -100% | |
| Feb 16, 2017 | ALKS Alkermes Plc. | Ehrich Elliot | EVP, R&D &CMO, Alkermes, Inc. | Sell | 11,000 | $56.68 | $623,441.49 | -6.6% | |
| Feb 16, 2017 | PAHC Phibro Animal Health Corp | Miller Larry Lee | Chief Operating Officer | Sell | 4,588 | $30.00 | $137,640.00 | -100% | |
| Feb 15, 2017 | JNJ Johnson & Johnson | Stoffels Paulus | Exec VP, Chief Scientific Off | Sell | 22,000 | $117.29 | $2,580,274.40 | -14.7% | |
| Feb 15, 2017 | PAHC Phibro Animal Health Corp | Carlson Gerald K | Director | Sell | 12,000 | $29.77 | $357,240.00 | -100% | |
| Feb 14, 2017 | MRK Merck & Co., Inc. | Karachun Rita A | Sr. VP Fince-global Controller | Sell | 2,954 | $64.73 | $191,226.60 | -20.2% | |
| Feb 14, 2017 | IRWD Ironwood Pharmaceuticals Inc | Gilbert Halley E | Chief Legal Officer | Sell | 37,385 | $16.75 | $626,198.75 | -100% | |
| Feb 13, 2017 | PAHC Phibro Animal Health Corp | Miller Larry Lee | Chief Operating Officer | Sell | 97,229 | $30.37 | $2,952,575.12 | -100% | |
| Feb 9, 2017 | PAHC Phibro Animal Health Corp | Dagger Thomas G | SVP, Gen Counsel And Corp Secr | Sell | 5,893 | $30.27 | $178,381.11 | -100% | |
| Feb 8, 2017 | MRK Merck & Co., Inc. | Russo Patricia F | Director | Sell | 5,000 | $64.42 | $322,121.00 | -27.6% | |
| Feb 7, 2017 | CANN Trees Corp (colorado) | Feinsod Michael | Director, 10% Owner | Sell | 200,000 | $1.25 | $250,000.00 | -15.4% | |
| Feb 7, 2017 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 953 | $43.32 | $41,287.11 | -43.8% | |
| Feb 7, 2017 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 953 | $43.34 | $41,299.57 | -43.8% | |
| Feb 7, 2017 | NBIX Neurocrine Biosciences Inc | Lloyd-Smith Malcolm49 | Chief Regulatory Officer | Sell | 843 | $43.35 | $36,544.81 | -43.8% | |
| Feb 6, 2017 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 3,010 | $43.18 | $129,971.80 | -1.2% | |
| Feb 6, 2017 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 963 | $43.14 | $41,543.82 | -0.8% | |
| Feb 6, 2017 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 727 | $43.13 | $31,355.51 | -0.6% | |
| Feb 6, 2017 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 727 | $43.15 | $31,370.05 | -1.2% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.